Company news
CAMP4 Therapeutics Corporation news in 2025
CAMP4 Therapeutics Corporation's news releases, calls and decks from 2025, newest first.
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
December 18, 2025
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
December 18, 2025
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 12, 2025
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights
November 6, 2025
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
October 1, 2025
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
September 10, 2025
eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors
August 19, 2025
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
August 14, 2025
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting
May 16, 2025
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
May 13, 2025
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
April 28, 2025
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
March 27, 2025
CAMP4 Appoints Multiple Industry Veterans to its Board of Directors
March 18, 2025
Decks in 2025
- Investor Presentation (May 2025)
Investor deck · 35 slides · May 16, 2025
- Investor Presentation (January 2025)
Investor deck · 32 slides · Jan 7, 2025